Brokerages Expect Collegium Pharmaceutical Inc (COLL) Will Post Earnings of -$0.30 Per Share

Equities analysts expect that Collegium Pharmaceutical Inc (NASDAQ:COLL) will report earnings per share of ($0.30) for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Collegium Pharmaceutical’s earnings, with the lowest EPS estimate coming in at ($0.40) and the highest estimate coming in at ($0.12). Collegium Pharmaceutical posted earnings of ($0.45) per share during the same quarter last year, which would indicate a positive year over year growth rate of 33.3%. The business is expected to announce its next quarterly earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Collegium Pharmaceutical will report full year earnings of ($1.41) per share for the current fiscal year, with EPS estimates ranging from ($1.50) to ($1.19). For the next year, analysts forecast that the business will post earnings of $0.18 per share, with EPS estimates ranging from ($0.45) to $1.09. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.02. The business had revenue of $73.10 million for the quarter, compared to analysts’ expectations of $72.21 million. Collegium Pharmaceutical had a negative return on equity of 61.82% and a negative net margin of 39.10%. The firm’s quarterly revenue was up 1930.6% on a year-over-year basis.

A number of equities research analysts have commented on COLL shares. Cantor Fitzgerald started coverage on Collegium Pharmaceutical in a report on Monday, June 11th. They set a “buy” rating and a $40.00 price target on the stock. BidaskClub raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a report on Thursday, June 21st. Zacks Investment Research raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a report on Monday, April 16th. ValuEngine cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Monday, July 2nd. Finally, Piper Jaffray Companies set a $34.00 price target on Collegium Pharmaceutical and gave the company a “buy” rating in a report on Wednesday, July 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $31.71.

In other news, COO Joseph Ciaffoni sold 79,683 shares of Collegium Pharmaceutical stock in a transaction dated Friday, June 1st. The stock was sold at an average price of $22.59, for a total value of $1,800,038.97. Following the sale, the chief operating officer now directly owns 174,089 shares of the company’s stock, valued at $3,932,670.51. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alison B. Fleming sold 4,096 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $27.00, for a total value of $110,592.00. Following the completion of the sale, the insider now directly owns 53,362 shares in the company, valued at $1,440,774. The disclosure for this sale can be found here. Insiders sold 243,779 shares of company stock worth $5,980,331 over the last ninety days. Insiders own 25.76% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Wellington Shields Capital Management LLC bought a new stake in shares of Collegium Pharmaceutical in the first quarter worth about $204,000. Atria Investments LLC bought a new stake in shares of Collegium Pharmaceutical in the second quarter worth about $201,000. EagleClaw Capital Managment LLC bought a new stake in shares of Collegium Pharmaceutical in the first quarter worth about $220,000. Stifel Financial Corp bought a new stake in shares of Collegium Pharmaceutical in the first quarter worth about $224,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in shares of Collegium Pharmaceutical in the first quarter worth about $260,000. 92.35% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:COLL traded up $0.35 on Thursday, reaching $18.03. 970,816 shares of the company’s stock traded hands, compared to its average volume of 500,254. The company has a quick ratio of 0.80, a current ratio of 0.82 and a debt-to-equity ratio of 3.94. The stock has a market cap of $587.36 million, a PE ratio of -7.30 and a beta of 0.51. Collegium Pharmaceutical has a 12 month low of $9.01 and a 12 month high of $29.90.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Recommended Story: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply